- Home
- HRMY vs VERA Comparison
HRMY vs VERA Comparison
Compare HRMY & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- VERA
- Stock Information
- Founded
- HRMY 2017
- VERA 2016
- Country
- HRMY United States
- VERA United States
- Employees
- HRMY N/A
- VERA N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- VERA Health Care
- Exchange
- HRMY Nasdaq
- VERA Nasdaq
- Market Cap
- HRMY 1.5B
- VERA 1.5B
- IPO Year
- HRMY 2020
- VERA 2021
- Fundamental
- Price
- HRMY $31.40
- VERA $24.09
- Analyst Decision
- HRMY Strong Buy
- VERA Buy
- Analyst Count
- HRMY 9
- VERA 9
- Target Price
- HRMY $50.44
- VERA $62.13
- AVG Volume (30 Days)
- HRMY 912.0K
- VERA 1.3M
- Earning Date
- HRMY 11-04-2025
- VERA 11-05-2025
- Dividend Yield
- HRMY N/A
- VERA N/A
- EPS Growth
- HRMY 50.44
- VERA N/A
- EPS
- HRMY 3.17
- VERA N/A
- Revenue
- HRMY $825,944,000.00
- VERA N/A
- Revenue This Year
- HRMY $20.68
- VERA N/A
- Revenue Next Year
- HRMY $15.93
- VERA N/A
- P/E Ratio
- HRMY $9.92
- VERA N/A
- Revenue Growth
- HRMY 21.13
- VERA N/A
- 52 Week Low
- HRMY $25.52
- VERA $18.53
- 52 Week High
- HRMY $40.93
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- HRMY 63.59
- VERA 34.53
- Support Level
- HRMY $27.66
- VERA $23.05
- Resistance Level
- HRMY $30.96
- VERA $26.16
- Average True Range (ATR)
- HRMY 1.25
- VERA 1.61
- MACD
- HRMY 0.54
- VERA -0.82
- Stochastic Oscillator
- HRMY 92.89
- VERA 13.44
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.